lunes, 15 de mayo de 2017

Adult Non-Hodgkin Lymphoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Adult Non-Hodgkin Lymphoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

National Cancer Institute

Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version


Changes to This Summary (05/12/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Armitage et al. as reference 10.
Revised text to state that if the clinical pattern of relapse suggests that the disease is behaving in a more aggressive manner, a biopsy should be performed, if feasible. Also revised text to state that the 5-year overall survival (OS) rate was more than 50% for patients who had biopsy-proven, aggressive-histology transformation in several multicenter cohort studies employing rituximab plus anthracycline or platinum-based chemotherapy, or similar therapy followed by autologous or allogeneic stem cell transplantation (cited Sarkozy et al. as reference 21).
Added Leblond et al. as reference 27.
Added text to state that the central nervous system (CNS)-International Prognostic Index (IPI) is a tool used to predict which patients have a risk of CNS relapse that is above 10%. It was developed by the German Lymphoma Study Group and validated by the British Columbia Cancer Agency database; four to six of the IPI risk factors and the involvement of the kidneys or adrenal glands were used to define the high-risk group that might benefit from CNS prophylaxis (cited Schmitz et al. as reference 29).
Revised text to state that lenalidomide with or without rituximab also shows response rates of around 50% in relapsed patients, with even higher response rates for previously untreated patients.
Added text to state that for patients with follicular lymphoma, a positive positron emission tomography (PET) result after therapy has a worse prognosis; however, it is unclear whether a positive PET result is predictive when further or different therapy is implemented (cited Pyo et al. as reference 7).
Revised text to state that a randomized trial of 401 patients comparing eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with three cycles of CHOP with involved-field radiation therapy was initially reported as having an OS advantage for the combined-modality arm at 5 years, but a reevaluation for OS at 18 years showed no difference in either arm of the study (cited Stephens et al. as reference 6).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: May 12, 2017

No hay comentarios:

Publicar un comentario